Oppenheimer & Co
KYNB icon

Oppenheimer & Co’s Kyntra Bio KYNB Stock Holding History

Oppenheimer & Co’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$157K Buy
+23,672
New +$175K ﹤0.01% 1665

Other funds holding KYNB

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return
AIM
Axiom Investment Management New York $121M AUM
Harbour Investments
Harbour Investments Madison, Wisconsin $6.75B AUM 16.25% 1-Year Est. Return
NFL
Nova Financial LLC Tucson, Arizona $238M AUM

Oppenheimer & Co's KYNB Position: Q3 2026 in Review

Oppenheimer & Co opened a new position in Kyntra Bio (KYNB) in Q3 2026: 23,672 shares worth $157K. The stake represents ﹤0.01% of the portfolio and ranks #1665 among its holdings.

21 funds tracked by Wall St. Rank hold KYNB as of Q3 2026.

  • Oppenheimer & Co held 23,672 shares of Kyntra Bio worth $157K as of Q3 2026.
  • Kyntra Bio was a new Oppenheimer & Co position in Q3 2026.
  • Kyntra Bio made up ﹤0.01% of Oppenheimer & Co's portfolio in Q3 2026, its #1665 holding.
  • 21 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.